DrugPatentWatch Database Preview
Try a free trial
See Plans and Pricing
« Back to Dashboard
Summary for Patent: 7,906,342
|Title:||Monitoring treatment of cancer patients with drugs targeting EGFR pathway using mass spectrometry of patient samples|
|Abstract:||Methods using mass spectral data analysis and a classification algorithm provide an ability to determine whether a non-small-cell lung cancer patient, head and neck squamous cell carcinoma or colorectal cancer patient has likely developed a non-responsiveness to treatment with a drug targeting an epidermal growth factor receptor pathway. As the methods of this disclosure require only simple blood samples, the methods enable a fast and non-intrusive way of measuring when drugs targeting the EGFR pathway cease to be effective in certain patients. This discovery represents the first known example of true personalized selection of these types of cancer patients for treatment using these classes of drugs not only initially, but during the course of treatment.|
|Inventor(s):||Roder; Heinrich (Steamboat Springs, CO), Tsypin; Maxim (Steamboat Springs, CO), Grigorieva; Julia (Steamboat Springs, CO)|
|Assignee:||Biodesix, Inc. (Steamboat Springs, CO)|
|Patent Claims:||1. A method of facilitating treatment of a non-small cell lung cancer (NSCLC) comprising the steps of: 1) assigning a baseline class label for the patient using a classifier
operating on integrated intensity values at pre-defined m/z ranges in mass-spectral data obtained from a blood-based sample of the patient and a training set comprising class-labeled spectra from other patients, the baseline class label indicating
whether the patient is likely to benefit from administration of a drug targeting an epidermal growth factor receptor pathway, wherein if the baseline class label is "good" (or the equivalent), the drug is administered to the patient; and 2) thereafter,
while the patient is being treated with the drug, a) obtaining a mass spectrum of a blood-based sample of the patient, b) performing one or more predefined pre-processing steps on the mass spectrum, c) obtaining integrated intensity values of selected
features in said spectrum at said one or more predefined m/z ranges after the pre-processing steps on the mass spectrum have been performed, and d) assigning a further class label for the sample using the classifier and the training set, the further
class label indicating whether the patient has developed a non-responsiveness to the treatment with the said drug wherein the drug is selected from the group of drugs consisting of gefitinib or equivalent thereof; erlotinib or equivalent thereof and
cetuximab or equivalent thereof.
2. The method of claim 1, wherein the patient is a male smoker or male ex-smoker.
3. The method of claim 1, wherein step 2) including sub-steps a)-d) are performed periodically during the course of treatment of the patient.
|Applicant||Tradename||Biologic Ingredient||Dosage Form||BLA||Number||Approval Date||Patent No.||Assignee||Estimated Patent Expiration||Status||Orphan||Source|
|Imclone||ERBITUX||cetuximab||VIAL; INTRAVENOUS||125084||001||2004-06-18||Try a Free Trial||Biodesix, Inc. (Steamboat Springs, CO)||2026-03-31||RX||Orphan||search|
|>Applicant||>Tradename||>Biologic Ingredient||>Dosage Form||>BLA||>Number||>Approval Date||>Patent No.||>Assignee||>Estimated Patent Expiration||>Status||>Orphan||>Source|
|Country||Patent Number||Publication Date|
|World Intellectual Property Organization (WIPO)||2007126758||Jan 10, 2008|
|World Intellectual Property Organization (WIPO)||2007126758||Nov 08, 2007|
|World Intellectual Property Organization (WIPO)||2010085234||Jul 29, 2010|
|World Intellectual Property Organization (WIPO)||2010085235||Jul 29, 2010|
|United States of America||2007231921||Oct 04, 2007|
|>Country||>Patent Number||>Publication Date|
Make Better Decisions: Try a trial or see plans & pricing
Serving hundreds of leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.